Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Moncyte Health OY has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner within 1 distinct art unit. Such a focused presence at the USPTO indicates that the applicant is currently managing a singular point of tension in their patent prosecution process.
The busiest examiner for the portfolio is MONSHIPOURI, MARYAM, who is responsible for 1 pending office action. With a busiest examiner pending count of 1, the applicant's entire pending docket is concentrated under this specific individual. This allows for a targeted prosecution strategy that addresses the specific preferences and prior art interpretations of this single examiner, as only 1 matter is assigned to this individual.
The presence of only 1 pending office action suggests a low volume of current conflict with the patent office. Because the 1 distinct examiner and 1 distinct art unit represent the entirety of the pending workload, the practitioner can dedicate full attention to the specific technical hurdles present in this case. This streamlined structure minimizes the complexity of tracking deadlines or varying examiner behaviors across the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.2% | +37.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266448 | METHOD FOR DETERMINING A LIKELIHOOD OF A SUBJECT TO RESPOND TO LIPID LOWERING THERAPY | MONSHIPOURI, MARYAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266448 | METHOD FOR DETERMINING A LIKELIHOOD OF A SUBJECT TO RESPOND TO LIPID LOWERING THERAPY | MONSHIPOURI, MARYAM | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18266448 | METHOD FOR DETERMINING A LIKELIHOOD OF A SUBJECT TO RESPOND TO LIPID LOWERING THERAPY | MONSHIPOURI, MARYAM | 1651 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMoncyte Health OY has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maryam Monshipouri has the most, with 1 of Moncyte Health OY's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
